Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficiency of antiemetic drugs was investigated in 36 children with neoplasia (mainly of hematopoietic system) in the course of 83 cycles of chemotherapy. The following antiemetic drugs were investigated: Fenactil (brand of chlorpromazine), Torecan (brand of thienylpromazine maleate), Aviomarin (brand of dimenhydrinate), Decadron (brand of dexamethasone), Primperan (brand of metoclopramid), and placebo. The most efficient was dexamethasone which prevented vomiting in 54% cycles of chemotherapy and diminished their intensity in the remaining cycles. No adverse reactions were noted. Efficacy of Fenactil, Torecan, Aviomarin, and Primperan was similar to that of placebo.
 ...
PMID:[Assessment of the efficacy of drugs used in prevention of vomiting during anticancer therapy in children]. 226 93

Comparative study was performed for assessing the postoperative anti-emetic and emesis preventive effect of domperidone. It has been found that the emesis preventive effect of Motilium tablet is identical with the effect of the well known Daedalon (Dramamin) and Torecan. From the therapeutic aspect it is of value especially in controlling nausea and in the prevention of subsequent vomiting following the use of rectal anti-emetics. This difference is attributable to the oral route of administration. Considering the lack of toxic effects domperidone is the most favourable.
 ...
PMID:The importance of domperidone (Motilium) in controlling postoperative nausea and vomiting. 228 18

The author summarizes the theoretical aspects of vomiting and alleviation of the same by surveying the respective scientific communications with special regard to thiethylperazine. The antiemetic effect of the Hungarian preparation containing thiethyilperazine (Torecan inj., EGIS Pharmaceuticals) is evaluated by the controlled clinical examination of patients receiving combined cytostatic treatment. According to the results Torecan proved to be significantly more effective in the alleviation of the emetic effect of the cytostatics than placebo.
 ...
PMID:Torecan, a review of references and clinical control examinations. 237 82

The influence of fluid intake and hydration rate on the frequency of vomiting was evaluated during 254 outpatient cisplatin infusions administered to 60 patients. The basic antiemetic regimen was consistent and used metoclopramide hydrochloride (Reglan) 2 mg/kg/dose (means = 150 mg) starting 30 minutes before cisplatin for a total of three doses; dexamethasone (Decadron) mean - 15 mg - and lorazepam (Ativan) 1 mg intravenous bolus before cisplatin, along with thiethlperazine maleate (Torecan) given routinely throughout the treatment beginning the evening before. Only 20% (38/192) of patients experienced symptoms of vomiting when hydrated at a rate of greater than 333 cc/hour as opposed to 44% (27/62) patients hydrated at a rate of 300 cc/hour or less (p = 0.01). Patients whose oral intake ranged from 400 cc to 1000 cc experienced noticeably less vomiting (14%) than patients who either refused fluids (39%, p = 0.001) or exceeded 1000 cc oral intake (36%, p less than 0.05) during treatment. Manipulation of total fluid intake (IV plus oral), although not statistically significant, seemed to affect the incidence of vomiting. By maintaining a positive intake/output ratio greater than 1, patients were able to decrease their vomiting episodes. Patients who gained weight during the treatment experienced significantly fewer episodes of vomiting (29%) than those who either lost or maintained their weight (71%). Findings suggest that manipulating both oral and IV fluid intake as well as the IV fluid rate may reduce symptoms of vomiting in the outpatient cisplatin setting.
 ...
PMID:Effects of fluid manipulation on the incidence of vomiting during outpatient cisplatin infusion. 292 70

In cytostatic drug treatment, nausea and vomiting are very frequent, unpleasant and undesirable side effects that cause considerable discomfort to the patient. However, many established antiemetics (Torecan, haloperidol, Valium, Largactil etc.) have not shown significant antiemetic activity in the patients to whom cytostatics were applied. In our controlled randomized clinical trial, the antiemetic activity of methylprednisolone was investigated and compared with placebo (10 ml saline) and Torecan. All the compounds were injected before cis-platinum administration, knowing that this agent induces vomiting in almost 100% of patients. Ninety patients entered the study and have been evaluated. The results of the trial have shown that methylprednisolone in the single dose of 250 mg applied i.v. 2 h before injection of a cytostatic agent experienced pronounced antiemetic activity in 48% of the patients (15/31), as compared to Torecan 21% (6/29) and placebo 13% (4/30). This difference was statistically significant (P less than 0.01). No side effects were recorded after methylprednisolone application. The results of the study showed that methylprednisolone possesses a pronounced antiemetic activity in almost half of the patients treated with cis-platinum.
 ...
PMID:Methylprednisolone as an antiemetic in patients on cis-platinum chemotherapy. Results of a controlled randomized study. 634 Mar

The occurring frequency of 14 most common chemotherapy and anti-nausea drug side-effects was examined. The studies were performed on 29 women with ovarian cancer treated by total number of 125 chemotherapy courses (schedule PAC and Acy) and additionally, in order to eliminate nausea caused by the chemotherapy, by anti-nausea drugs (Zofran, Solu-Medrol, Droperidol, Metoclopramide + Fenactil, Torecan). Zofran caused the fewest number of side-effects, solu-medrol inhibited nausea and vomiting significantly, however it caused many side-effects such as flush on a face, restlessness, incitement and headaches. Torecan did not prevent patients from vomiting. The greatest number of side-effects was observed after droperidol and metoclopramide + fenactil treatment.
 ...
PMID:[Side effects of drug treatment for ovarian cancer after administration of antiemetic drugs]. 814 54